{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001631","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.141872+00:00","generated_at":"2026-06-19T06:31:16.773577+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GlycoMimetics CSO John Magnani to depart March 31; consulting through June 2024","bullets":["Dr. John Magnani, SVP Research and CSO, employment ends March 31, 2023.","Severance of $40,000 payable in equal installments over 3 months after separation.","Company will pay COBRA premiums for 15 months post-separation.","Consulting agreement from April 1, 2023 through June 30, 2024 for continued equity vesting.","Consulting services provided at request of CEO or designee."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001631","json":"https://secwatch.observer/filing/0001558370-23-001631.json","markdown":"https://secwatch.observer/filing/0001558370-23-001631.md","text":"https://secwatch.observer/filing/0001558370-23-001631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/0001558370-23-001631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/glyc-20230221x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:31:16.773577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d0e1badab","claim":"John Magnani departed as Senior Vice President of Research and Chief Scientific Officer at CRESCENT BIOPHARMA, INC..","evidence_excerpt":"On February 21, 2023, GlycoMimetics, Inc. (the “ Company ”) and Dr. John Magnani, the Company’s Senior Vice President of Research and Chief Scientific Officer, entered into an agreement (the “ Transition Agreement ”) pursuant to which the Company and Dr. Magnani have agreed that his employment with the Company will end on March 31, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/0001558370-23-001631-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"agreed that his employment will end"},{"label":"Role","value":"Senior Vice President of Research and Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}